A number of other equities research analysts have also recently weighed in on the company. UBS set a €120.00 ($142.86) price target on Merck KGaA and gave the company a buy rating in a report on Monday, October 23rd. equinet set a €112.00 ($133.33) price target on Merck KGaA and gave the company a buy rating in a report on Thursday, August 31st. Societe Generale set a €103.00 ($122.62) price target on Merck KGaA and gave the company a neutral rating in a report on Tuesday, September 5th. Goldman Sachs Group set a €105.00 ($125.00) price target on Merck KGaA and gave the company a neutral rating in a report on Wednesday, September 6th. Finally, Independent Research set a €105.00 ($125.00) price target on Merck KGaA and gave the company a neutral rating in a report on Monday, August 28th. Eleven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company currently has an average rating of Buy and an average target price of €108.52 ($129.20).
Merck KGaA (FRA:MRK) opened at €89.82 ($106.93) on Friday. Merck KGaA has a 52 week low of €87.99 ($104.75) and a 52 week high of €115.00 ($136.90).
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
What are top analysts saying about Merck KGaA? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck KGaA and related companies.